Open AccessPerformance of tacrolimus in hospitalized patients with steroid-refractory acute severe ulcerative colitis
Author(s) -
Péter Hoffmann,
Cyrill Wehling,
Johannes Krisam,
Jan Pfeiffenberger,
Nina Belling,
Annika Gauss
Publication year - 2019
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v25.i13.1603
Subject(s) - tacrolimus , medicine , ulcerative colitis , colectomy , clinical endpoint , gastroenterology , calcineurin , inflammatory bowel disease , hepatology , refractory (planetary science) , disease , clinical trial , transplantation , physics , astrobiology
Acute severe ulcerative colitis unresponsive to systemic steroid treatment is a life-threatening medical condition requiring hospitalization and often colectomy. Despite the increasing choice of medical therapy options for ulcerative colitis, the condition remains a great challenge in the field of inflammatory bowel diseases (IBD). The performance of the calcineurin inhibitor tacrolimus in this clinical setting is insufficiently elucidated.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom